AddedRisk Factors
Although our insurance coverage reflects deductibles, self-insured retentions, limits of liability, and similar provisions that we believe are reasonable based on our operations, the coverage under our insurance programs may not be adequate to protect us in all
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
and on acceptable terms, or at all. Should a supply disruption result in the inability to obtain pharmaceutical solutions necessary for patient care, our business, financial condition, and results of operations could be negatively impacted.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
adverse effect on our business, financial condition, and results of operation.” Furthermore, our third-party providers’ existing safety systems, data backup, access protection, user management, information technology emergency planning, and other security measures may not be sufficient to prevent data loss or long-term network outages.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
Regulatory agencies may initiate administrative proceedings alleging violations of statutes and regulations arising from our services, or reimbursement of those services, and seek to impose monetary penalties on us. We could be required to pay substantial
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
amount of our voting power, even if such amount is less than 50%, it is able to strongly influence or effectively control our decisions, and KKR Stockholder has the right to nominate individuals to our board of directors under the existing stockholders agreement.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, KKR Stockholder and its affiliates are able to determine the outcome of all matters requiring stockholder approval and are able to cause or prevent a change of control of the Company or a change in the composition of our board of directors and could preclude any acquisition of the Company. This concentration of voting control could deprive you of an opportunity to receive a premium for your shares of common stock as part of a sale of the Company and ultimately might affect the market price of our common stock.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
Further, in Canada, the Personal Information Protection and Electronic Documents Act, or PIPEDA, and similar provincial laws may impose obligations with respect to processing personal information. PIPEDA requires companies to obtain an individual’s consent when collecting, using, or disclosing that individual’s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual’s consent.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
As of December 31, 2024, we had approximately $2,546.8 million outstanding under the First Lien Term Loan Facility. As of December 31, 2024, we had $63.3 million outstanding under the Revolving Credit Facility, with an available borrowing capacity
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
we were unable to repay the amounts due and payable under the First Lien Facilities, those lenders could proceed against the collateral granted to them to secure that indebtedness, and we could be forced into bankruptcy or liquidation.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
On June 30, 2023, we entered into amendments to our First Lien Facilities, and as part of those amendments we transitioned from the use of London Interbank Offered Rate, or LIBOR, to Secured Overnight Financing Rate, or SOFR.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are a “controlled company” within the meaning of the rules of Nasdaq and the rules of the SEC and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. You do not have the same protections afforded to stockholders of other companies that are subject to such requirements.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
KKR Stockholder beneficially owns approximately 54.2% of the voting power of common stock. As a result, we are a “controlled company” within the meaning of the corporate governance standards of Nasdaq. Under these rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain corporate governance requirements, including the requirement that:
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedRisk Factors
•a majority of our board of directors consist of “independent directors” as defined under the rules of Nasdaq;
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RewordedRisk Factors
Our second amended and restated certificate of incorporation provides that unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or if such court does not have jurisdiction, another state or the federal courts (as appropriate) located within the State of Delaware) will will, to the fullest extent permitted by law, be the sole and exclusive forum for substantially all disputes between us and our stockholders and the federal district courts will be the exclusive forum for Securities Act and Exchange Act claims, which could limit our stockholders’ ability to bring a suit in a different judicial forum than they may otherwise choose for disputes with us or our directors, officers, team members or stockholders.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, we had $63.3 $475.0 million outstanding of borrowing capacity available under the Revolving Credit Facility, with an available borrowing capacity Revolver as there were no borrowings under the Revolving Credit Facility Revolver or letters of approximately $411.7 million, credit outstanding, and $61.8 $62.8 million of letters of credit outstanding under the LC Facility.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our future effective tax rates and the value of our deferred tax assets could be adversely affected by changes in tax laws, including impacts of the Tax Cuts and Jobs Act of Public Law No. 115-97, or the TCJA, and the Coronavirus Aid, Relief and Economic Security One Big Beautiful Bill Act, or the CARES Act. enacted July 4, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The sale is subject to customary closing conditions, including the expiration or termination of the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and certain other antitrust laws. laws and other laws (such as the State of California Office of Healthcare Affordability requiring a cost and market impact review).
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Termination of one or more of our facilities from the Medicare program for failure to satisfy the program’s conditions of participation, or the imposition of alternative sanctions, could disrupt operations, require significant attention by management, or have a material adverse effect on our reputation, business, financial condition, and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Inclement weather, natural disasters, acts of terrorism, riots, civil insurrection, social unrest or other acts of violence, looting, protests, strikes, or street demonstrations demonstrations, or pandemics, may prevent or hinder our employees from providing authorized goods and services and our patients and customers from receiving those goods and services.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
More recently, in June 2022, the Federal Trade Commission, or FTC, announced an inquiry regarding the role of PBMs and stated its intent to closely scrutinize the impact of PBM rebates and fees on patients and payers. payers, the FTC issued an interim report in June 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Existing laws and regulations are constantly evolving, and new laws and regulations that apply to our business are being introduced at every level of government in the United States. States, as well as in foreign jurisdictions where we currently operate or may in the future operate.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any inability to offset increased brand name or generic drug acquisition costs or to modify our activities to lessen the financial impact of such increased costs could have a significant adverse effect on our operating results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to prevent our competitors from using names, logos, slogans, and domain names similar to ours, or if we are prevented by our competitors from using certain names, logos, slogans and domain names, consumer confusion could result, the perception of our brands and services could be negatively affected, and our revenue and profitability could suffer as a result.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures, and other strategic initiatives. initiatives, including the pending sale of our Community Living business, as well as organic growth.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
During the past several years, third-party Third-party healthcare payors, such as federal and state governments, insurance companies and employers, have undertaken undertaken, and will likely continue to undertake, cost containment initiatives.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We maintain general liability insurance to provide coverage to us and our subsidiaries against certain of these non-governmental litigation claims and potential litigation risks.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The Company has determined the divestiture of the Community Living business represents a strategic shift that will have a major effect on its business and therefore met the criteria for classification as discontinued operations. As a result, the financial results of the Community Living business, which were previously reported as part of our Provider Services segment, have been classified as discontinued operations in the audited consolidated statements of operations, and its assets and liabilities have been classified as held for sale for all periods presented. Unless otherwise noted, amounts and disclosures throughout this Management’s Discussion and Analysis relate to our continuing operations. Refer to Part II, Item 8. Note 2 for additional information regarding discontinued operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Completed two underwritten secondary offerings of our common stock by affiliates of Kohlberg Kravis Roberts & Co. L.P. and certain members of management, which were completed in June 2025 and October 2025. As a result of these offerings, we are no longer a “controlled company” within the meaning of the corporate governance standards of Nasdaq
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Repurchased 1,500,000 shares of common stock in connection with the October 2025 secondary offering
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Net income increased by $173.7 million from a net loss of $68.9 million to net income of $104.8 million
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Diluted income per share increased by $0.82 from diluted loss per share of $(0.34) to diluted income per share of $0.48
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In addition to organic growth, we have grown through acquisitions that have deepened and expanded our presence in current markets and facilitated entry into attractive adjacent markets.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On January 17, 2025, the Company entered into a definitive agreement to sell its Community Living business to National Mentor Holdings, Inc., for $835.0 million in cash upon closing, subject to certain post-closing adjustments. We entered into the transaction in order to streamline our service offerings and further focus on the senior and specialty populations. The transaction is currently expected to close in the first fiscal quarter of 2026, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The Company has determined the divestiture of the Community Living business represents a strategic shift that will have a major effect on its business and has concluded the criteria for classification as discontinued operations were met during the first fiscal quarter of 2025. Accordingly, the Community Living business is reported as discontinued operations in accordance with Accounting Standards Codification (“ASC”) 205-20, Discontinued Operations. The related assets and liabilities of the Community Living business are classified as assets and liabilities held for sale in the accompanying consolidated balance sheets, and the results of operations from the Community Living business are classified as discontinued operations in the consolidated statements of operations. Applicable amounts in prior years have been recast to conform to this discontinued operations presentation. The Community Living business was historically presented as a part of the Provider Services reportable segment.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The following table reconciles net income (loss) from continuing operations to EBITDA and Adjusted EBITDA:
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
obligations of $13.5 million, offset by proceeds from shares issued under share-based compensation plan of $25.3 million and other financing activities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Our 2025 and 2024 goodwill impairment analyses concluded that the fair value of each reporting unit was in excess of the carrying amount of each reporting unit. Subsequent to completing each goodwill impairment test, no indicators of impairment were identified.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
•Paydown and modification of our First Lien Facility, including interest rate refinancings that resulted in interest savings
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
•$63.3 million of equity awards granted to management and certain other full-time employees at the time of our IPO
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
•7.7 million restricted stock units granted to certain full-time employees in the second fiscal quarter of 2024, as disclosed in connection with our IPO
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
•Completed eight acquisitions within our Pharmacy Solutions and Provider Services segments
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
•Announcement of the pending divestiture of our Community Living business on January 20, 2025
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
•Net loss decreased by $136.3 million from $156.8 million to $20.5 million; when excluding the approximately $30 million quality incentive payment (“QIP”) received in 2023, net loss decreased by $166.5 million
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
•Adjusted EBITDA(1) increased by $50.3 million, or 9.3%, to $588.1 million; when excluding the approximately $30 million QIP received in 2023, Adjusted EBITDA increased by $80.5 million or 15.9%
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
are positioned to identify potential medical problems and avoid adverse events due to our highly proximate position to patients and attentive care protocols, as evidenced by these quality metrics.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
On January 30, 2024, we completed our IPO of 53,333,334 shares of common stock at a price of $13.00 per share and a concurrent offering of 8,000,000 6.75% tangible equity units (“TEUs”) with a stated amount of $50.00 per Unit (collectively, the “IPO Offerings”). The net proceeds from the IPO Offerings amounted to $656.5 million and $389.0 million for the common stock and TEUs, respectively, after deducting underwriting discounts, commissions, and offering-related expenses. The shares of common stock and TEUs began trading on the Nasdaq Global Select Market on January 26, 2024 under the ticker symbols “BTSG” and “BTSGU,” respectively.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
We used a portion of the net proceeds received from the IPO Offerings to (i) repay all indebtedness outstanding under the Second Lien Facility, (ii) repay all indebtedness outstanding under the Revolving Credit Facility, (iii) repay $343.3 million outstanding aggregate amount under the First Lien Facility, and (iv) pay certain expenses in the offering. We retained the remaining proceeds for general corporate purposes. Additionally, we paid $22.7 million of termination fees in connection with the termination of our monitoring agreement with Kohlberg Kravis Roberts & Co. L.P. (“KKR”) and Walgreens Boots Alliance, Inc. (together with KKR, the “Managers”) (the “Monitoring Agreement”).
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
We granted approximately $63.3 million in non-cash share-based compensation with equity awards to our management and certain other full-time employees in January 2024 at the time of the IPO Offerings. Additionally, as previously disclosed in connection with the IPO, we granted approximately $100.0 million in non-cash share-based compensation equity awards, which equates to approximately 7.7 million restricted stock units, to certain full-time employees in the second quarter of fiscal year 2024.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RemovedMD&A
As discussed under Part I, Item 1. “Business”, the Company was eligible to receive incentive payments in connection with a payor contract based on the Company's Net Promoter Score (“NPS”) achieved from surveys performed directly by the payor. During the second fiscal quarter of 2023, our Infusion and Specialty Pharmacy services earned a quality incentive payment (“QIP”) of approximately $30 million. The Company did not receive a QIP during the year ended December 31, 2024. The QIP program has reached its conclusion.
Read it in 10-K Mar 6, 2025 at sec.govopen_in_new
RewordedMD&A
($ in thousands) Rate Long-term obligation and note payable Interest Expense December 31, December 31, December 31, December 31, Fiscal Year Fiscal Year 2025 2024 2023 2025 2024 2023 2025 2024 2023 First Lien - payable to lenders at SOFR plus — 8.72% — $ — $ 1,719,360 — $ 21,217 — $ 146,167 18,151 applicable margin First Lien Tranche B-2 and B-3 - payable to lenders at — 8.97% — 1,189,975 15,106 104,190 — — — 12,923 SOFR plus applicable margin First Lien Incremental Term Loan Tranche B-4 - — — — — 176,223 — 150,759 payable to lenders at SOFR plus applicable margin First Lien Incremental Term Loan Tranche B-5 - 6.22% 6.86% — 2,521,255 2,546,787 — 10,353 — 146,482 8,857 payable to lenders at SOFR plus applicable margin Second Lien - payable to lenders at SOFR plus — 13.97% — 450,000 5,239 62,012 — — — 4,482 applicable margin Revolving Credit Loans - payable to lenders at SOFR 6.47% 7.61% 9.59% — 50,000 387 3,988 — — 331 plus applicable margin Swingline Loans and Base Rate Loans - payable to 8.50% 9.75% 11.75% — 63,300 700 12,392 12,243 6,996 10,602 lenders at ABR plus applicable margin Amortizing Notes 31,360 53,804 — 5,726 — 4,183 4,899 Notes payable and other 17,129 19,428 4,356 886 316 2 Amortization of deferred financing costs & other, net — — (18,573) (4,009) (1,236) (20,774) of interest income from cash flow hedges Total debt $ 2,569,744 $ 2,683,319 $ 3,414,391 157,311 $ 228,386 $ 324,593 190,546 Less: debt issuance costs, net 62,200 72,736 50,177 Total debt, net of debt issuance costs 2,507,544 2,610,583 3,364,214 Less:
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
($ in thousands) For the The Years Ended December 31, 2025 2024 2023 Net loss income (loss) from continuing operations $ (20,521) 104,796 $ (156,835) (68,931) Income tax benefit (14,217) (20,578) expense (benefit) 33,145 (26,387) Interest expense, net 228,386 324,593 157,311 190,546 Depreciation and amortization 204,482 202,336 162,948 162,144 EBITDA $ 398,130 458,200 $ 349,516 257,372 Non-cash share-based compensation (1) 69,174 3,917 59,164 61,336 Acquisition, integration, and transaction-related costs (2) 34,869 20,734 40,424 31,953 Restructuring and divestiture-related and other costs (3) 38,031 21,848 59,782 61,688 Legal costs and settlements (4) — 21,886 127,695 Significant projects (5) — 2,604 8,379 Management fees (6) — 23,381 5,631 Unreimbursed COVID-19 related costs — 88 Total adjustments $ 189,945 159,370 $ 188,292 202,848 Adjusted EBITDA $ 588,075 617,570 $ 537,808 460,220
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
(shares in thousands) For the The Years Ended December 31, 2025 2024 2023 Diluted EPS $ (0.09) 0.48 $ (1.31) (0.34) Non-cash share-based compensation (1) 0.34 0.03 0.27 0.30 Acquisition, integration, and transaction-related costs (1) 0.17 0.18 0.16 Restructuring and divestiture-related and other costs (1) 0.19 0.17 0.27 0.31 Legal costs and settlements (1) — 0.11 1.01 Significant projects (1) — 0.01 0.07 Management fee (1) — 0.12 0.04 Unreimbursed COVID-19 related costs (1) — 0.00 Income tax impact on adjustments (2)(3) (0.29) (0.10) (2) (0.20) (0.32) Adjusted EPS $ 0.56 1.00 $ 0.07 0.35 Weighted average common shares outstanding used in calculating diluted U.S.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
For information of regarding our results of operations for the year ended December 31, 2023 2024 compared to the year ended December 31, 2022, 2023, refer to Exhibit 99.1 of our Current Report on Form 8-K, filed with the SEC on June 10, 2025, which contains retrospective revisions for the changes resulting from the discontinued operations, where applicable, to Item 7.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue attributable to Home and Community Pharmacy was $2,349.9 million for the year ended December 31, 2025, as compared with $2,228.3 million for the year ended December 31, 2024, as compared with $1,921.6 million for the year ended December 31, 2023, an increase of $306.7 $121.6 million or 16.0% 5.5% attributable to volume growth. mix changes in prescriptions dispensed.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
($ in thousands) For the Years Ended December 31, 2025 2024 2023 Revolving Credit Facility Rollforward Beginning Revolving Credit Facility balance $ 63,300 $ 50,700 $ 74,800 Borrowings (repayments) (Repayments) borrowings of swingline debt, net (63,300) 12,600 (24,100) Ending Revolving Credit Facility balance $ — $ 63,300 $ 50,700 Calculation of Revolving Credit Facility and LC Facility availability Revolving Credit Facility and LC Facility limit $ 540,000 $ 530,000 540,000 Less: outstanding Revolving Credit Facility balance — 63,300 50,700 Less: outstanding letters of credit subject to LC Sublimit — 6,632 — Less: outstanding letters of credit under the LC Facility 62,790 61,821 54,279 End of period Revolving Credit Facility and LC Facility availability 477,210 414,879 418,389 End of period cash balance 61,253 13,071 88,370 60,954 Total Liquidity, end of period $ 476,132 565,580 $ 431,460 475,833
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in financing activities was $76.9 $157.9 million for the year ended December 31, 2023, 2025, primarily attributable to repayments on our long-term debt of $30.4 $50.3 million, net repayments on our Revolving Credit Facility of $24.1 $63.3 million, repurchase of shares of common stock of $43.2 million in connection with the October 2025 secondary offering, and payment of finance lease obligations of $11.6 million, and other financing activities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue attributable to Home Health Personal Care was $1,041.3 $402.2 million for the year ended December 31, 2025, as compared with $385.9 million for the year ended December 31, 2024, as compared with $921.4 million for the year ended December 31, 2023, an increase of $119.9 $16.3 million or 13.0%. 4.2%.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease primarily resulted from a decrease in both the variable-rate and applicable margin for the year ended December 31, 2025 as compared to the prior periods and lower outstanding term debt as compared to the prior period and period, offset by a $3.9 $20.1 million increase decrease in interest income related to cash flow hedges of interest rate risk.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue attributable to Community and Rehab Care was $1,470.9 $294.7 million for the year ended December 31, 2025, as compared with $276.6 million for the year ended December 31, 2024, as compared with $1,382.3 million for the year ended December 31, 2023, an increase of $88.6 $18.1 million or 6.4%. 6.5%.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenues were $11,266.5 $12,910.6 million for the year ended December 31, 2025, as compared with $10,072.2 million for the year ended December 31, 2024, as compared with $8,826.2 million for the year ended December 31, 2023, an increase of $2,440.3 $2,838.4 million or 27.6%. 28.2%.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Interest expense, net was $228.4 $157.3 million for the year ended December 31, 2025, as compared with $190.5 million for the year ended December 31, 2024, as compared with $324.6 million for the year ended December 31, 2023, a decrease of $96.2 $33.2 million or 29.6%. 17.4%.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new